For diabetes and obesity, the benefits of GLP-1s depend on long-term use
Dendrou CA, Fugger L, Friese MA
GLP-1 injections: Evidence and efficacy In contrast to patches, GLP-1 injections have extensive clinical evidence supporting their effectiveness: Clinical trial results Wegovy (semaglutide) : The STEP clinical trials involved thousands of participants and showed average weight loss of 15% after 68 weeks
It offers powerful antioxidant support and neutralises free radicals
As per the data from the University of California Health Data Warehouse, Ozempic (semaglutide, a GLP-1 RA) users have increased from 569 to 7667 to 22,891 in 2019, 2020, and 2022, respectively [5]